Saitama Medical University International Medical Center, one of Japan's leading hospitals for the treatment of oncology, cardiology, and stroke cases, has joined the TriNetX Network to utilize global real-world data to better understand rare diseases, treatments, and outcomes, as well as provide additional clinical trial opportunities to its patients.

"Novel therapies may have unanticipated outcomes across diverse patient populations," said Isamu Koyama, Hospital Director Emeritus, Saitama Medical University International Medical Center and Senior Management Director, Saitama Medical University Foundation. "It is important to share real-world data on those treatments and outcomes from an international perspective, and that is precisely what TriNetX brings to the investigators at Saitama Medical University as well as peer institutions across the TriNetX Network."

TriNetX is the largest and fastest-growing collaborative research network comprised of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation.

"One of the most important values of our health system is patient-centered care, which always places the interest of patients first," said Toshiaki Saeki, Director of Saitama Medical University International Medical Center. "TriNetX is the global leader in the field of secondary use of real-world data for clinical and observational research and is in the best position to effectively connect our hospital with other medical institutions and corresponding real-world data from around the world."

"We are thrilled to welcome Saitama Medical University to the TriNetX Network," said Shogo Wakabayashi, Country Manager, Japan, TriNetX, "We look forward to helping the university's investigators generate real-world evidence and increase the clinical trial opportunities available for their patients."